Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Rebecca Adams, Jack E M Coumbe, Ben G T Coumbe, Jennifer Thomas, Zena Willsmore, Marija Dimitrievska, Monica Yasuzawa-Parker, Maximilian Hoyle, Suhaylah Ingar, Jenny L C Geh, Alastair D MacKenzie Ross, Ciaran Healy, Sophie Papa, Katie E Lacy & Sophia N Karagiannis. (2022) BRAF inhibitors and their immunological effects in malignant melanoma. Expert Review of Clinical Immunology 18:4, pages 347-362.
Read now
Read now
Michael G. White, Robert Szczepaniak Sloane, Russell G. Witt, Alexandre Reuben, Pierre Olivier Gaudreau, Miles C. Andrews, Ningping Feng, Sarah Johnson, Caleb A. Class, Christopher Bristow, Khalida Wani, Courtney Hudgens, Luigi Nezi, Teresa Manzo, Mariana Pettaccia De Macedo, Jianhua Hu, Richard Davis, Hong Jiang, Peter Prieto, Elizabeth Burton, Patrick Hwu, Hussein Tawbi, Jeffrey Gershenwald, Alexander J. Lazar, Michael T. Tetzlaff, Willem Overwijk, Scott E Woodman, Zachary A. Cooper, Joseph R. Marszalek, Michael A. Davies, Timothy P. Heffernan & Jennifer A. Wargo. (2021) Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. OncoImmunology 10:1.
Read now
Read now
Michael J. Carr, James Sun, Zeynep Eroglu & Jonathan S. Zager. (2020) An evaluation of encorafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy 21:2, pages 155-161.
Read now
Read now
Paolo A. Ascierto & Reinhard Dummer. (2018) Immunological effects of BRAF+MEK inhibition. OncoImmunology 7:9.
Read now
Read now
Nienke de Haas, Coco de Koning, Lisanne Spilgies, I. Jolanda M. de Vries & Stanleyson V. Hato. (2016) Improving cancer immunotherapy by targeting the STATe of MDSCs. OncoImmunology 5:7.
Read now
Read now
Martina Sanlorenzo, Igor Vujic, Adrian Moy, Pietro Quaglino, Maria Teresa Fierro, Loretta Gammaitoni, Fabrizio Carnevale-Schianca, Massimo Aglietta & Dario Sangiolo. (2015) Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. Expert Opinion on Biological Therapy 15:10, pages 1491-1500.
Read now
Read now
Laura J Vella, Miles C Andrews, Andreas Behren, Jonathan Cebon & Katherine Woods. (2014) Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. Expert Review of Clinical Immunology 10:8, pages 1107-1123.
Read now
Read now
Articles from other publishers (26)
Lisa H. Butterfield & Yana G. Najjar. (2023) Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology.
Crossref
Crossref
David Miller, Kevin Emerick, Vishal Patel, Sonia Cohen, Isaac Brownell & Donald Lawrence. (2023) Lacking Overall IMspiration for Triplet Therapy in Melanoma? A Review of the Interim Analysis of IMspire150. Journal of Cutaneous Oncology 1:1.
Crossref
Crossref
Margaret K. Callahan & Paul B. Chapman. (2022) PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600–Mutated Melanoma. Journal of Clinical Oncology 40:13, pages 1393-1395.
Crossref
Crossref
Hannah M. Knochelmann, Michael Brandon Ware, Aditya Rali, Susanne Linderman, Jessica G. Shantha, David H. Lawson, Melinda Yushak, Robert Swerlick, Chrystal M. Paulos, Steven Yeh & Ragini Kudchadkar. (2022) Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition. Frontiers in Oncology 12.
Crossref
Crossref
Thomas Jung, Maximilian Haist, Michael Kuske, Stephan Grabbe & Matthias Bros. (2021) Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond. International Journal of Molecular Sciences 22:18, pages 9890.
Crossref
Crossref
Briana R. Halle & Douglas B. Johnson. (2021) Defining and Targeting BRAF Mutations in Solid Tumors. Current Treatment Options in Oncology 22:4.
Crossref
Crossref
Alexandra M. Haugh, April K.S. Salama & Douglas B. Johnson. (2021) Advanced Melanoma. Hematology/Oncology Clinics of North America 35:1, pages 111-128.
Crossref
Crossref
Ilaria Proietti, Nevena Skroza, Simone Michelini, Alessandra Mambrin, Veronica Balduzzi, Nicoletta Bernardini, Anna Marchesiello, Ersilia Tolino, Salvatore Volpe, Patrizia Maddalena, Marco Di Fraia, Giorgio Mangino, Giovanna Romeo & Concetta Potenza. (2020) BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers 12:7, pages 1823.
Crossref
Crossref
Paolo A. Ascierto & Michael B. Atkins. 2020. Cutaneous Melanoma. Cutaneous Melanoma
1215
1241
.
Laura Croce, Francesca Coperchini, Flavia Magri, Luca Chiovato & Mario Rotondi. (2019) The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget 10:61, pages 6623-6640.
Crossref
Crossref
Alessandro Rossi, Michela Roberto, Martina Panebianco, Andrea Botticelli, Federica Mazzuca & Paolo Marchetti. (2019) Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. European Journal of Pharmacology 862, pages 172621.
Crossref
Crossref
Alexandra M. Haugh & Douglas B. Johnson. (2019) Management of V600E and V600K BRAF-Mutant Melanoma. Current Treatment Options in Oncology 20:11.
Crossref
Crossref
Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur & Antoni Ribas. (2019)
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with
BRAF
V600-mutated Metastatic Melanoma
. Clinical Cancer Research 25:11, pages 3239-3246.
Crossref
Crossref
Ryan J. Sullivan, Omid Hamid, Rene Gonzalez, Jeffrey R. Infante, Manish R. Patel, F. Stephen Hodi, Karl D. Lewis, Hussein A. Tawbi, Genevive Hernandez, Matthew J. Wongchenko, YiMeng Chang, Louise Roberts, Marcus Ballinger, Yibing Yan, Edward Cha & Patrick Hwu. (2019) Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nature Medicine 25:6, pages 929-935.
Crossref
Crossref
Meredith S. Pelster & Rodabe N. Amaria. (2019) Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Therapeutic Advances in Medical Oncology 11, pages 175883591983082.
Crossref
Crossref
Paolo A. Ascierto & Michael B. Atkins. 2018. Cutaneous Melanoma. Cutaneous Melanoma
1
27
.
F. De Santis, M. Del Vecchio, L. Castagnoli, F. De Braud, S. Di Cosimo, D. Franceschini, G. Fucà, J. Hiscott, K.J. Malmberg, N. McGranahan, F. Pietrantonio, L. Rivoltini, S. Sangaletti, E. Tagliabue, C. Tripodo, C. Vernieri, L. Zitvogel, S.M. Pupa & M. Di Nicola. (2018) Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. Cytokine & Growth Factor Reviews 44, pages 1-10.
Crossref
Crossref
Marvin Kuske, Dana Westphal, Rebekka Wehner, Marc Schmitz, Stefan Beissert, Christian Praetorius & Friedegund Meier. (2018) Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Pharmacological Research 136, pages 151-159.
Crossref
Crossref
Matthew J. Wongchenko, Antoni Ribas, Brigitte Dréno, Paolo A. Ascierto, Grant A. McArthur, Jorge D. Gallo, Isabelle A. Rooney, Jessie Hsu, Hartmut Koeppen, Yibing Yan & James Larkin. (2018)
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with
BRAF
mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib
. Pigment Cell & Melanoma Research 31:4, pages 516-522.
Crossref
Crossref
M. Di Nicola, L. Apetoh, M. Bellone, M.P. Colombo, G. Dotti, S. Ferrone, M. Muscolini, J. Hiscott, A. Anichini, S.M. Pupa, F.de Braud & M. Del Vecchio. (2017) Innovative Therapy, Monoclonal Antibodies and Beyond. Cytokine & Growth Factor Reviews 38, pages 1-9.
Crossref
Crossref
Matthew J. Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas Amler, Yibing Yan & Antoni Ribas. (2017)
Gene Expression Profiling in
BRAF
-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
. Clinical Cancer Research 23:17, pages 5238-5245.
Crossref
Crossref
Erez Nissim Baruch, Amy Lauren Berg, Michal Judith Besser, Jacob Schachter & Gal Markel. (2017) Adoptive T cell therapy: An overview of obstacles and opportunities. Cancer 123:S11, pages 2154-2162.
Crossref
Crossref
Jason A Chesney, Robert A Mitchell & Kavitha Yaddanapudi. (2017) Myeloid-derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy. Journal of Leukocyte Biology 102:3, pages 727-740.
Crossref
Crossref
Sangeetha M. Reddy, Alexandre Reuben & Jennifer A. Wargo. (2016) Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports 18:7.
Crossref
Crossref
Stephen Mok, Jennifer Tsoi, Richard C Koya, Siwen Hu-Lieskovan, Brian L West, Gideon Bollag, Thomas G Graeber & Antoni Ribas. (2015) Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 15:1.
Crossref
Crossref
J. Charles, C. Martel, F. de Fraipont, M.-T. Leccia, C. Robert & B. Busser. (2014) M?canismes de r?sistance aux inhibiteurs de BRAF. Annales de Dermatologie et de V?n?r?ologie 141:11, pages 671-681.
Crossref
Crossref